Previous 10 | Next 10 |
2023-10-01 14:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-09-29 09:58:19 ET More on Corcept Therapeutics Corcept Therapeutics: Far More Constructive With Korlym Resolve (Rating Upgrade) Corcept Therapeutics Incorporated (CORT) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Corcept Therapeutics ...
2023-09-28 16:30:23 ET More on Teva, Novartis Novartis: Buy This Dividend Aristocrat For Consistent Income Teva: Focus On Innovation And Growth Means The Times They Are A Changing Eli Lilly benefits as judge overturns $176.5M verdict in Teva patent case Novar...
2023-09-27 17:48:46 ET More on Eli Lilly, Teva Eli Lilly: Don't Be Fooled By Greed Teva: Focus On Innovation And Growth Means The Times They Are A Changing Eli Lilly: A Potential Game Changer For Weight Management And Cardiovascular Health GLP-1 drugs may alr...
2023-09-20 06:56:03 ET More on Alvotech, Teva, etc. Teva: Focus On Innovation And Growth Means The Times They Are A Changing Alvotech: FDA Overhang Remains, Remaining Constructive, Initiate Hold Alvotech GAAP EPS of -$0.39, revenue of $22.72M Teva CEO sees no...
2023-09-14 10:28:04 ET Summary Teva Pharmaceutical Industries has faced significant challenges and a decline in shareholder value over the past decade. The company has resolved its opioid litigation with U.S. states and is focusing on maximizing growth in innovative products and b...
2023-09-12 15:49:54 ET More on Biogen Seeking Alpha’s Quant Rating on Biogen Historical earnings data for Biogen Financial information for Biogen Biogen Inc. ( BIIB ) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript) Stoc...
2023-09-11 12:50:27 ET Teva Pharmaceutical Industries Limited (TEVA) Morgan Stanley 21st Annual Global Healthcare Conference 2023 Call September 11, 2023, 08:40 AM ET Company Participants Richard Francis - Chief Executive Officer Conference Call Participants ...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Morgan Stanley Global Healthcare Conference on Monday, September 11, 2023. The presentation will begin at 8:40 A.M. Eastern Time. To access a live webc...
Teva will share 16 data presentations across its neuroscience portfolio including AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 (olanzapine) and AJOVY ® (fremanezumab) injection Presentation highlights include data for AUSTEDO in the tardive dyskinesia (TD) START study on real-...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emerg...
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...